Hypoxia, angiogenesis, and oral cancer metastasis

Oral Cancer Metastasis

Volumn , Issue , 2010, Pages 299-321

  Le, Quynh Thu ^a   Courter, Donald ^a   Giaccia, Amato ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855441284     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0775-2_14     Document Type: Chapter

References (106)

1. Adams RH, Wilkinson GA, Weiss C et al (1999) Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13:295-306
2. Allan AL, George R, Vantyghem SA et al (2006) Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169:233-246
3. Argiris A, Haraf DJ, Kies MS et al (2003) Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist 8:350-360
4. Ascani G, Balercia P, Messi M et al (2005) Angiogenesis in oral squamous cell carcinoma. Acta Otorhinolaryngol Ital 25:13-17
5. Barbera-Guillem E, Nyhus JK, Wolford CC et al (2002) Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 62:7042-7049
6. Beasley NJ, Wykoff CC, Watson PH et al (2001) Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61:5262-5267
7. Beasley NJ, Leek R, Alam M et al (2002) Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62:2493-2497
8. Brantley-Sieders DM, Caughron J, Hicks D et al (2004) EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 117:2037-2049
9. Brantley-Sieders DM, Fang WB, Hicks DJ et al (2005) Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. Faseb J 19:1884-1886
10. Brantley-Sieders DM, Fang WB, Hwang Y et al (2006) Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 66:10315-10324
11. Brizel DM, Scully SP, Harrelson JM et al (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941-943
12. Brizel DM, Dodge RK, Clough RW et al (1999) Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53:113-117
13. Brizel DM, Prosnitz RG, Hunter S et al (2004) Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 58:1418-1423
14. Brockstein B, Haraf DJ, Rademaker AW et al (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15:1179-1186
15. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416
16. Bruckner K, Pasquale EB, Klein R (1997) Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 275:1640-1643
17. Cheng N, Brantley DM, Chen J (2002) The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 13:75-85
18. Chi JT, Wang Z, Nuyten DS et al (2006) Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Med 3:e47
19. Chung CD, Patel VP, Moran M et al (2000) Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 165:3722-3729
20. De Schutter H, Landuyt W, Verbeken E et al (2005) The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/-chemotherapy. BMC Cancer 5:42
21. Denko NC, Fontana LA, Hudson KM et al (2003) Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22:5907-5914
22. Dunst J, Stadler P, Becker A et al (2001) Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 177:469-473
23. Dvorak HF, Nagy JA, Feng D et al (1999) Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237:97-132
24. Eisma RJ, Spiro JD, Kreutzer DL (1997) Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 174:513-517
25. Eisma RJ, Spiro JD, Kreutzer DL (1999) Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope 109:687-693
26. Erler JT, Bennewith KL, Nicolau M et al (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-1226
27. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
28. Evans SM, Koch CJ (2003) Prognostic significance of tumor oxygenation in humans. Cancer Lett 195:1-16
29. Evans SM, Du KL, Chalian AA et al (2007) Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys 69:1024-1031
30. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676
31. Fyles A, Milosevic M, Hedley D et al (2002) Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20:680-687
32. Gatenby RA, Kessler HB, Rosenblum JS et al (1988) Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838
33. Gerety SS, Wang HU, Chen ZF et al (1999) Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4:403-414
34. Giaccia A, Siim BG, Johnson RS (2003) HIF-1 as a target for drug development. Nat Rev Drug Discov 2:803-811
35. Gleich LL, Biddinger PW, Duperier FD et al (1997) Tumor angiogenesis as a prognostic indicator in T2-T4 oral cavity squamous cell carcinoma: a clinical-pathologic correlation. Head Neck 19:276-280
36. Goldman CK, Kendall RL, Cabrera G et al (1998) Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 95:8795-8800
37. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47
38. Heroult M, Schaffner F, Augustin HG (2006) Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 312:642-650
39. Holland SJ, Gale NW, Mbamalu G et al (1996) Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature 383:722-725
40. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
41. Imagawa S, Goldberg MA, Doweiko J et al (1991) Regulatory elements of the erythropoietin gene. Blood 77:278-285
42. Imagawa S, Yamaguchi Y, Higuchi M et al (2001) Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea-hypopnea syndrome. Blood 98:1255-1257
43. Jablonska E, Piotrowski L, Jablonski J et al (2002) VEGF in the culture of PMN and the serum in oral cavity cancer patients. Oral Oncol 38:605-609
44. Janssen HL, Haustermans KM, Sprong D et al (2002) HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 54:1537-1549
45. Jonathan RA, Wijffels KI, Peeters W et al (2006) The prognostic value of endogenous hypoxiarelated markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 79:288-297
46. Kaanders JH, Wijffels KI, Marres HA et al (2002) Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62:7066-7074
47. Kennedy KA, Teicher BA, Rockwell S et al (1980) The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol 29:1-8
48. Koong AC, Denko NC, Hudson KM et al (2000) Candidate genes for the hypoxic tumor phenotype. Cancer Res 60:883-887
49. Koukourakis MI, Bentzen SM, Giatromanolaki A et al (2006) Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727-735
50. Kowalski LP, Carvalho AL, Martins Priante AV et al (2005) Predictive factors for distant metastasis from oral and oropharyngeal squamous cell carcinoma. Oral Oncol 41:534-541
51. Kunkel M, Reichert TE, Benz P et al (2003) Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97:1015-1024
52. Kyzas PA, Cunha IW, Ioannidis JP (2005a) Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a metaanalysis. Clin Cancer Res 11:1434-1440
53. Kyzas PA, Stefanou D, Batistatou A et al (2005b) Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study. Cancer Lett 225:297-304
54. Kyzas PA, Stefanou D, Batistatou A et al (2005c) Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 131:624-630
55. Lartigau E, Le Ridant AM, Lambin P et al (1993) Oxygenation of head and neck tumors. Cancer 71:2319-2325
56. Le QT, Sutphin PD, Raychaudhuri S et al (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67
57. Le QT, Denko NC, Giaccia AJ (2004) Hypoxic gene expression and metastasis. Cancer Metastasis Rev 23:293-310
58. Le QT, Shi G, Cao H et al (2005) Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23:8932-8941
59. Le QT, Kong C, Lavori PW et al (2007) Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69:167-175
60. Liao CT, Wang HM, Chang JT et al (2007) Analysis of risk factors for distant metastases in squamous cell carcinoma of the oral cavity. Cancer 110:1501-1508
61. Linderholm BK, Lindh B, Beckman L et al (2003) Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer 4:340-347
62. Ljungkvist AS, Bussink J, Kaanders JH et al (2007) Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167:127-145
63. Lopez de Cicco R, Watson JC, Bassi DE et al (2004) Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression. Clin Cancer Res 10:4480-4488
64. Maeda T, Matsumura S, Hiranuma H et al (1998) Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status. J Clin Pathol 51:771-775
65. Masood R, Kumar SR, Sinha UK et al (2006) EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer 119:1236-1248
66. Mayer A, Wree A, Hockel M et al (2004) Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res 64:5876-5881
67. Mayer A, Hockel M, Vaupel P (2005a) Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res 11:7220-7225
68. Mayer A, Hockel M, Wree A et al (2005b) Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers. Clin Cancer Res 11:2768-2773
69. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124
70. Nordsmark M, Overgaard J (2000) A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57:39-43
71. Nordsmark M, Alsner J, Keller J et al (2001) Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 84:1070-1075
72. Nordsmark M, Bentzen SM, Rudat V et al (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77:18-24
73. Nordsmark M, Eriksen JG, Gebski V, Nordsmark M, Eriksen JG, Gebski V et al (2007) Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83:389-397
74. Ogawa K, Pasqualini R, Lindberg RA et al (2000) The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19:6043-6052
75. Oliver RJ, Woodwards RT, Sloan P et al (2004) Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer 40:503-507
76. Overgaard J, Eriksen JG, Nordsmark M et al (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757-764
77. Pazouki S, Chisholm DM, Adi MM et al (1997) The association between tumour progression and vascularity in the oral mucosa. J Pathol 183:39-43
78. Penfold CN, Partridge M, Rojas R et al (1996) The role of angiogenesis in the spread of oral squamous cell carcinoma. Br J Oral Maxillofac Surg 34:37-41
79. Petrik D, Lavori PW, Cao H et al (2006) Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 24:5291-5297
80. Presta LG, Chen H, O'Connor SJ et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599
81. Rabinovich GA, Ariel A, Hershkoviz R et al (1999) Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 97:100-106
82. Raza SM, Fuller GN, Rhee CH et al (2004) Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 10:212-221
83. Riedel F, Gotte K, Schwalb J et al (2000) Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 257:332-336
84. Rubinstein N, Alvarez M, Zwirner NW et al (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5:241-251
85. Rudat V, Vanselow B, Wollensack P et al (2000) Repeatability and prognostic impact of the pretreatment pO (2) histography in patients with advanced head and neck cancer. Radiother Oncol 57:31-37
86. Rudat V, Stadler P, Becker A et al (2001) Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlenther Onkol 177:462-468
87. Salven P, Manpaa H, Orpana A et al (1997) Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 3:647-651
88. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
89. Schilling D, Bayer C, Geurts-Moespot A et al (2007) Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines. BMC Cancer 7:143
90. Semenza GL, Nejfelt MK, Chi SM et al (1991) Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the erythropoietin gene. Proc Natl Acad Sci USA 88:5680-5684
91. Singhal H, Bautista DS, Tonkin KS et al (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605-611
92. Smith BD, Smith GL, Carter D et al (2000) Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18:2046-2052
93. Sprague LD, Mengele K, Schilling D et al (2006) Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells. Oncology 71:282-291
94. Sprague LD, Tomaso H, Mengele K et al (2007) Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. Oncol Rep 17:1259-1268
95. Stroka DM, Burkhardt T, Desbaillets I et al (2001) HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. Faseb J 15:2445-2453
96. Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549
97. Tse GM, Chan AW, Yu KH et al (2007) Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma. Ann Surg Oncol 14:3558-3565
98. Vihanto MM, Plock J, Erni D et al (2005) Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin. Faseb J 19:1689-1691
99. Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230-1237
100. Wang HU, Chen ZF, Anderson DJ (1998) Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93:741-753
101. Winter SC, Shah KA, Han C et al (2006) The relation between hypoxia-inducible factor (HIF) - 1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107:757-766
102. Winter SC, Buffa FM, Silva P et al (2007) Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 67:3441-3449
103. Zelzer E, Levy Y, Kahana C et al (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. Embo J 17:5085-5094
104. Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545
105. Ziemer LS, Koch CJ, Maity A et al (2001) Hypoxia and VEGF mRNA expression in human tumors. Neoplasia 3:500-508
106. Zundel W, Schindler C, Haas-Kogan D et al (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14:391-396